Levothyroxine absorption test—results and follow up of patients from a single center
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Introduction: Treating primary hypothyroidism with appropriate weight-based dosing is usually straightforward. When supraphysiologic doses of thyroxine are required, it is important to know the reason behind the increased requirement. When compliance with medication is assured and when there are no drug interactions resulting in increased thyroxine requirements, a levothyroxine absorption test (LT4AT) could be performed to diagnose the coexistence of malabsorption. Materials and Methods: This was a single-center, retrospective chart review. Patients who had undergone LT4AT between 2018 and 2020 with a complete evaluation and follow-up records were reviewed. LT4AT and further evaluation (if necessary) were standardized, and details until the last review were obtained. Results: In all, 11 patients had complete records and follow-up details. The median age (range) of the cohort was 24 years (19 to 46), and the duration of hypothyroidism was 8 years (4 to 24). Seven had low absorption (<60%) in LT4AT of which two each had celiac disease and Helicobacter pylori infection; one had autoimmune gastritis, and in two the reasons of malabsorption was not known. The median follow-up duration was 13 months. Nine of 11 (81%) achieved euthyroid state with/without thyroxine dose reduction on follow-up. Conclusion: A high proportion of patients requiring supraphysiological doses of levothyroxine had occult malabsorptive states, some of which were curable. Even in those with pseudo-malabsorption, LT4AT helped in reinforcing compliance and thereby thyroxine dose reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“So far, the levothyroxine absorption test is not standardized [7-18], and multiple protocols have been published with differences regarding the test dose, formulations, test durations, frequency of blood collections, analyte (total T4, free T4), metric (absolute or relative peak or increment), and thresholds for normal absorption.”
From Levothyroxine Absorption Test With the Daily Levothyroxine Dose in Patients With “Refractory Hypothyroidism” (2025) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis
Centanni, M., Gargano, L., Canettieri, G., Viceconti, N., Franchi, A., Fave, G. D., & Annibale, B. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043903 · Cited by 329 · cited 1×
“Though there are no specific cut‐offs for identifying malabsorption, the dose of 2 mcg/kg was based on a study from 2006.[6] History pertaining to interaction with food/beverages/ naturopathic medicines/nutritional supplements; previous bowel surgeries; obvious gastrointestinal/malabsorption syndromes; allergies; seve…”
BackgroundA review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism
Colucci, P., Yue, C. S., Ducharme, M., Benvenga, S., Principal Scientist, L. A. C. I., Principal Scientist, L. A. C. I. A. P. C., President and CEO, L. A. C. I., & Professor of Medicine, D. (2010) · European Endocrinology · doi:10.17925/ee.2013.09.01.40 · Cited by 167 · cited 1×
“[1] This requires a fasting state, adequate pH in the stomach, and no interference in absorption from the lumen of the gut in a healthy individual.[2] However, LT4 absorption varies drastically and unpredictably when consumed with food and beverages, other medications (calcium salts, iron salts, aluminum salts, bile a…”
BackgroundPrevalence of Adult Celiac Disease in India: Regional Variations and Associations
Ramakrishna, B. S., Makharia, G. K., Chetri, K., Dutta, S., Mathur, P., Ahuja, V., Amarchand, R., Balamurugan, R., Chowdhury, S. D., Daniel, D., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.398 · Cited by 165
Gastrointestinal malabsorption of thyroxine
Virili, C., Antonelli, A., Santaguida, M. G., Benvenga, S., & Centanni, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00168 · Cited by 164 · cited 2×
“As the pH increases above 1, the aqueous solubility of LT4 reduces.[5] Hence, in disorders where parietal cells are destroyed or their action is inhibited, the LT4 dose needs to be increased to maintain normal TSH.”
BackgroundLocalization of human thyroxine absorption
HAYS, M. T. (1991) · Thyroid · doi:10.1089/thy.1991.1.241 · Cited by 138 · cited 1×
“Under optimum conditions, 60%–80% of orally administered LT4 is absorbed from the duodenum, jejunum, and ileum.[1] This requires a fasting state, adequate pH in the stomach, and no interference in absorption from the lumen of the gut in a healthy individual.”
BackgroundSucralfate causes malabsorption of L-thyroxine
Sherman, S. I., Tielens, E. T., & Ladenson, P. W. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90093-0 · Cited by 105
Treatment of Helicobacter pylori infection in atrophic gastritis
Lahner, E., Carabotti, M., & Annibale, B. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i22.2373 · Cited by 99
Autoimmune diseases in autoimmune atrophic gastritis.
Rodriguez-Castro, K. I., Franceschi, M., Miraglia, C., Russo, M., Nouvenne, A., Leandro, G., Meschi, T., Angelis, G. L. D., & Mario, F. D. (2018) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v89i8-s.7919 · Cited by 89
Celiac Disease and Glandular Autoimmunity
Kahaly, G. J., Frommer, L., & Schuppan, D. (2018) · Nutrients · doi:10.3390/nu10070814 · Cited by 84
Walker, J. N., Shillo, P., Ibbotson, V, Vincent, A., Karavitaki, N., Weetman, A. P., Wass, J. A. H., & Allahabadia, A. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-1035 · Cited by 70
Larizza, D., Calcaterra, V., Martinetti, M., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1272 · Cited by 54
Adherence to thyroid hormone replacement therapy: a retrospective, claims database analysis
Hepp, Z., Wyne, K., Manthena, S. R., Wang, S., & Gossain, V. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1486293 · Cited by 48
The levothyroxine absorption test: a four-year experience (2015-2018) at the Mayo Clinic
Gonzales, K. M., Stan, M. N., Morris, J. C., Bernet, V., & Castro, M. R. (2019) · Thyroid · doi:10.1089/thy.2019.0256 · Cited by 46 · cited 1×
“[9‐12] In studies that have followed up a cohort of patients who had underwent LT4AT, the majority (90%–95% of patients tested) had normal absorption test results – meaning that they had pseudo‐malabsorption.[8,10,11] In a study from Turkey, 2/5 patients who underwent LT4AT had lactose intolerance which was mitigated…”
BackgroundBugdaci, M. S., Zuhur, S. S., Sokmen, M., Toksoy, B., Albayrak, B., & Altuntas, Y. (2011) · Helicobacter · doi:10.1111/j.1523-5378.2011.00830.x · Cited by 41
Levothyroxine absorption test to differentiate pseudomalabsorption from true malabsorption
Ghosh, S., Pramanik, S., Biswas, K., Bhattacharjee, K., Sarkar, R., Chowdhury, S., & Mukhopadhyay, P. (2020) · European Thyroid Journal · doi:10.1159/000504218 · Cited by 39
Van Wilder, N., Bravenboer, B., Herremans, S., Vanderbruggen, N., & Velkeniers, B. (2017) · European Thyroid Journal · doi:10.1159/000452489 · Cited by 31
Drug absorption in celiac disease
Tran, T. H., Smith, C. J., & Mangione, R. A. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120689 · Cited by 29
The clinical utility of free thyroxine in oral levothyroxine absorption testing
Ching Sun, G. E., Pantalone, K. M., Faiman, C., Gupta, M., Olansky, L., & Hatipoglu, B. (2014) · Endocrine Practice · doi:10.4158/ep13487.or · Cited by 27 · cited 2×
“[9‐12] In studies that have followed up a cohort of patients who had underwent LT4AT, the majority (90%–95% of patients tested) had normal absorption test results – meaning that they had pseudo‐malabsorption.[8,10,11] In a study from Turkey, 2/5 patients who underwent LT4AT had lactose intolerance which was mitigated…”
BackgroundLevothyroxine absorption test results in patients with TSH elevation resistant to treatment
Yildirim Simsir, I., Soyaltin, U. E., & Ozgen, A. G. (2019) · Endocrine · doi:10.1007/s12020-019-01889-x · Cited by 16
Lewandowski, K. C., Dąbrowska, K., Komorowska-Dudek, I., & Lewiński, A. (2015) · Thyroid Research · doi:10.1186/s13044-015-0028-0 · Cited by 10
Cited by
Caron, P., Tudor, C., & Grunenwald, S. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf017 · Cited by 8
Metadata
- Authors
- Subramaniam, K., Babu, T., Sreevalsan, K. C., & Mathew, S.
- Affiliations
- Department of Endocrinology, Silverline Hospital, Kochi, Kerala, India
- Department of Biochemistry, Silverline Hospital, Kochi, Kerala, India
- Corresponding author
- Subramaniam, Karthik
- Venue
- Indian Journal of Endocrinology and Metabolism
- Published
- 2022-04-29
- Volume
- 27
- Issue
- 1
- Pages
- 32-36
- ISSN
- 2230-8210 (ISSN-L)
- 2230-9500
- PMC
- PMC10198188
- OpenAlex
- W4322747524
- Cited by
- 4
- References
- 20
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 1
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Indian Journal of Endocrinology and Metabolism (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Gastroenterology › Celiac Disease Research and Management
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- primary hypothyroidism, celiac disease, Helicobacter pylori infection, autoimmune gastritis, medication adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.